9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer

Clinical Cancer Research

Volumn 3, Issue 2, 1997, Pages 287-294

  De Souza, Paul L ^a,c   Cooper, Michael R ^a   Imondi, Anthony R ^b   Myers, Charles E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARBOXYLIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TOPOISOMERASE I INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0031020443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gibbons, R. P. Prostate cancer chemotherapy. Cancer (Phila.), 60: 586-587, 1987.
2. Meyer, J. S., Sufrin, G., and Martin, S. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol., 128: 1353-1356, 1982.
3. Schmid, H. P., McNeal, J. E., and Stamey, T. A. Observations on the doubling time of prostate cancer. Cancer (Phila.), 71: 2031-2040, 1993.
4. Theyer, G., Schirmbock, M., Thalhammer, T., Sherwood, E. R., Baumgartner, G., and Hamilton, G. Role of the mdr-1 encoded multiple drug resistance phenotype in prostate cancer cell lines. J. Urol., 150: 1544-1547, 1993.
5. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor type specificity, and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
6. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
7. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell une (DU 145). Int. J. Cancer, 27: 274-281, 1978.
8. Kaighn, M. E., Shankar Narayan, K., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17: 16-23, 1979.
9. Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu, Z., Kaighn, M. E., and Hart, I. R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res., 44: 3522-3529, 1984.
10. Buttke, T. M., McCubrey, J. A., and Owen, T. C. Use of an aqueous soluble tetrazolium/formazan assay to measure the viability and proliferation of lymphokine dependent ceil lines. J. Immunol. Methods, 157: 233-240, 1993.
11. Pretlow, T. G., Delmoro, C. M., Dilley, G. G, Spadafora, C. G., and Pretlow, T. P. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res., 51: 3814-3817, 1991.
12. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil. M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
13. Giovanella, B. C., Hinz, H. R., Kozielski, A. J., Stehlin, J. S., Silber, R., and Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res., 51: 3052-3055, 1991.
14. Takimoto, C. H., Klecker, R. W., Dahut, W. L., Yee, L. K., Strong, J. M., Allegra, C. J., and Grem, J. L. Analysis of the active from of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B, 655: 97-104, 1994.
15. Takimoto, C. H., Dahut, W., Harold, N., Morrison, G. B., Quin, M. F., Cullen, E., Liang, M. D., Arbuck, S. G., Chen, A., Hamilton, J. M., Allegra, C. J., Sorensen, J. M., and Grem, J. L. A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 15; 488, 1996.
16. Pantazis, P., Hinz, H. R., Mendoza, J. T., Kozielski, A. J., Williams, L. J., Stehlin, J. S., and Giovanella, B. C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res., 52: 3980-3987, 1992.
17. Pantazis, P., Kozielski, A. J., Vardeman D. M., Petry, E. R., and Giovanella, B. C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol. Res., 5: 273-281, 1993.
18. Hinz, H. R., Harris, N. J., Natelson, E. A., and Giovanella, B. C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice. Cancer Res., 54: 3096-3100, 1994.
19. Supko, J., and Malspeis, L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res., 53: 3062-3069, 1993.
20. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic environment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
21. Hertzberg, R. P., Caranfa, M. J., Kingsbury, W. D., Smith, B., Johnson, R. K., and Hecht, S. M. The biochemistry of camptothecin-topoisomerase I interaction. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 103-120. New York: Oxford University Press, 1991.
22. Fassberg, J., and Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 81: 676-684, 1992.
23. Burke, T. G., and Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem., 37: 40-46, 1994.
24. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy. Principles and Practice, Ed. 2, pp. 463-484. Philadelphia: Lippincott-Raven Publishers, 1996.
25. Suffness, M., and Cordeil, G. A. Camptothecins. In: A. Brossi fed.), The Alkaloids: Chemistry and Pharmacology, Vol. 25, pp. 73-89. Orlando, FL: Academic Press, 1985.
26. Wani, M. C., Ronman, P. E., Lindley, J. T., and Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem., 23: 554-560, 1980.
27. Supko, J. G., and Malspeis, L. A reversed phase HPLC method for determining camptothecin in plasma with specificity for the intact lactone form of the drug. J. Liq. Chromatogr., 14: 1779-1803, 1991.
28. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattem, M. R., Mong, S. M., O'Leary, J., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
29. Carter, H. B., Morell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E. J., Chan, D. W., Fozard, J. L., and Walsh, P. C. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res., 52: 3323-3328, 1992.